Investigational therapies for psoriasis.
As the pathogenesis of psoriasis is better understood, specific targeted therapies are being developed. In addition to alefacept, etanercept, efaluzimab, and infliximab, discussed in separate articles in this issue, numerous other investigational therapies are currently in clinical trials, some of which will likely be approved in the future. We review the most promising of these therapies and their mechanisms of action.
Cather
Jennifer Clay
JC
Texas Dermatology Associates, 5310 Harvest Hill, Dallas, TX 75230, USA. research@texasderm.com
Cather
John Christian
JC
Abramovits
William
W
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D003879:Dermatologic Agents / Q000627:therapeutic use; D015507:Drugs, Investigational; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D009539:Nicotinic Acids / Q000627:therapeutic use; D010778:Photochemotherapy; D011565:Psoriasis / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000187:drug effects; D012176:Retinoids
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D003879:Dermatologic Agents; D015507:Drugs, Investigational; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids; C472181:efalizumab